Can ceftriaxone (a third-generation cephalosporin) administered intramuscularly (IM) be used as a treatment for syphilis infection in patients allergic to penicillin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftriaxone IM for Syphilis Treatment

Ceftriaxone 1 gram IM daily for 10-14 days can be used as an alternative treatment for syphilis in penicillin-allergic patients, though it remains a second-line option with limited data compared to penicillin, and should be reserved for situations where penicillin desensitization is not feasible. 1, 2

Primary Treatment Remains Penicillin

  • Benzathine penicillin G is the gold standard for all stages of syphilis and should be the first-line treatment whenever possible 3, 2
  • For penicillin-allergic patients, penicillin desensitization followed by penicillin therapy is the strongly preferred approach, particularly when compliance cannot be ensured 2, 4
  • Skin testing can help clarify true penicillin allergy status before proceeding with alternatives 4

When Ceftriaxone Can Be Used

Dosing and Duration

  • The recommended ceftriaxone regimen is 1 gram daily (IM or IV) for 10-14 days for early syphilis 1, 2, 4
  • For neurosyphilis, ceftriaxone 2 grams daily IV for 10-14 days has limited supporting data but may be considered 1
  • Single-dose ceftriaxone is not effective and should never be used 4

Supporting Evidence

  • A 2022 network meta-analysis showed ceftriaxone had a higher serological response rate than penicillin at 6-month follow-up (RR 1.12,95% CI 1.02-1.23) 5
  • Multiple observational studies in HIV-infected patients demonstrated comparable efficacy between ceftriaxone and penicillin, with ≥4-fold decline in VDRL titers in 91% of patients 6, 7
  • A randomized trial from 1989 showed equivalent clinical and serological response between ceftriaxone and penicillin for primary and secondary syphilis 8

Critical Limitations and Caveats

Cross-Reactivity Warning

  • Patients with severe penicillin allergy (such as Stevens-Johnson syndrome) may also be allergic to ceftriaxone, as both are beta-lactam antibiotics 1, 9
  • Exercise extreme caution and consider alternative non-beta-lactam options (doxycycline or tetracycline) in patients with severe penicillin reactions 4

Data Gaps

  • The optimal dose and duration of ceftriaxone have not been definitively established 1
  • Evidence for ceftriaxone in late latent syphilis and tertiary syphilis is extremely limited 1
  • Efficacy data in HIV-infected patients, while promising, remain limited compared to penicillin 1

Alternative Non-Beta-Lactam Options

First-Line Alternatives (Non-Pregnant)

  • Doxycycline 100 mg orally twice daily is the preferred non-penicillin alternative: 14 days for early syphilis, 28 days for late latent syphilis 3, 2, 4
  • Tetracycline 500 mg orally four times daily (same duration as doxycycline) is effective but has more gastrointestinal side effects affecting compliance 2, 4

When These Cannot Be Used

  • If both penicillin and doxycycline allergies exist, tetracycline becomes the primary alternative 4
  • Erythromycin 500 mg orally four times daily for 14 days is less effective and should only be used when compliance can be absolutely ensured 4

Mandatory Follow-Up for Ceftriaxone-Treated Patients

  • Close serologic monitoring is required due to limited efficacy data for alternative therapies 2, 4
  • Quantitative nontreponemal tests (RPR or VDRL) should be performed at 6 and 12 months for early syphilis 3, 2
  • For HIV-infected patients, increase monitoring frequency to 3-month intervals (at 3,6,9, and 12 months) 3, 4
  • Treatment success is defined as a fourfold decline in nontreponemal titer within 6 months for early syphilis 3, 2

Absolute Contraindications to Ceftriaxone Use

Pregnancy

  • Ceftriaxone is inadequate for treating syphilis in pregnancy and does not reliably prevent congenital syphilis 2
  • All pregnant women with penicillin allergy must undergo desensitization followed by penicillin treatment—no exceptions 2, 4
  • Only penicillin has documented efficacy for preventing maternal transmission to the fetus 2
  • One case report showed successful prevention of congenital syphilis with ceftriaxone in a woman with Stevens-Johnson syndrome to penicillin, but this remains experimental and not guideline-recommended 9

Neurosyphilis

  • Alternative regimens for neurosyphilis are not adequately studied 4
  • Penicillin desensitization is strongly preferred for neurosyphilis treatment 1, 4
  • If ceftriaxone must be used for neurosyphilis, the dose is 2 grams daily IV (not IM) for 10-14 days, with very limited supporting data 1

Common Pitfalls to Avoid

  • Do not use oral penicillin preparations—they are completely ineffective for syphilis 2
  • Do not switch between different nontreponemal tests (VDRL vs RPR) when monitoring response, as results cannot be directly compared 2
  • Do not use azithromycin in the United States due to widespread macrolide resistance and documented treatment failures 1, 2
  • Do not rely on treponemal antibody tests (FTA-ABS, TP-PA) to monitor treatment response—they remain positive for life 3
  • Remember that 15-25% of successfully treated patients remain "serofast" with persistent low titers (<1:8) that do not indicate treatment failure 1, 3, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Syphilis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment for Primary Syphilis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Alternative Antibiotics for Syphilis in Patients Allergic to Both Penicillin and Doxycycline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.